Stock Scorecard
Stock Summary for X4 Pharmaceuticals Inc (XFOR) - $3.70 as of 1/31/2026 10:59:00 AM EST
Total Score
8 out of 30
Safety Score
25 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for XFOR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for XFOR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for XFOR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for XFOR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for XFOR (25 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for XFOR
Financial Details for XFOR
Company Overview |
|
|---|---|
| Ticker | XFOR |
| Company Name | X4 Pharmaceuticals Inc |
| Country | USA |
| Description | X4 Pharmaceuticals Inc. is a Boston-based clinical-stage biopharmaceutical company dedicated to developing breakthrough therapies for rare and serious diseases, particularly those related to back disorders. Leveraging its proprietary technology, X4 is advancing a promising pipeline of investigational therapies designed to meet critical unmet medical needs and improve patient outcomes. With a strong commitment to innovative clinical development and a clear focus on underserved patient populations, X4 is strategically positioned to make a significant impact in the biopharmaceutical sector and potentially establish itself as a leader in therapeutic solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 3.70 |
| Price 4 Years Ago | 29.79 |
| Last Day Price Updated | 1/31/2026 10:59:00 AM EST |
| Last Day Volume | 255,569 |
| Average Daily Volume | 590,088 |
| 52-Week High | 20.10 |
| 52-Week Low | 1.35 |
| Last Price to 52 Week Low | 174.07% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.68 |
| Sector PE | 188.49 |
| 5-Year Average PE | -21.65 |
| Free Cash Flow Ratio | 4.63 |
| Industry Free Cash Flow Ratio | 12.86 |
| Sector Free Cash Flow Ratio | 30.14 |
| Current Ratio Most Recent Quarter | 5.65 |
| Total Cash Per Share | 0.80 |
| Book Value Per Share Most Recent Quarter | 2.45 |
| Price to Book Ratio | 5.24 |
| Industry Price to Book Ratio | 64.54 |
| Sector Price to Book Ratio | 57.14 |
| Price to Sales Ratio Twelve Trailing Months | 9.52 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.05 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.56 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 87,437,000 |
| Market Capitalization | 323,516,900 |
| Institutional Ownership | 41.74% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 62.98% |
| Reported EPS 12 Trailing Months | -8.94 |
| Reported EPS Past Year | -4.12 |
| Reported EPS Prior Year | -0.71 |
| Net Income Twelve Trailing Months | -95,095,000 |
| Net Income Past Year | -37,450,000 |
| Net Income Prior Year | -101,167,000 |
| Quarterly Revenue Growth YOY | 215.20% |
| 5-Year Revenue Growth | -3.15% |
| Operating Margin Twelve Trailing Months | -1,281.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 69,856,000 |
| Total Cash Past Year | 55,699,000 |
| Total Cash Prior Year | 99,216,000 |
| Net Cash Position Most Recent Quarter | -6,206,000 |
| Net Cash Position Past Year | -19,726,000 |
| Long Term Debt Past Year | 75,425,000 |
| Long Term Debt Prior Year | 54,570,000 |
| Total Debt Most Recent Quarter | 76,062,000 |
| Equity to Debt Ratio Past Year | 0.23 |
| Equity to Debt Ratio Most Recent Quarter | 0.45 |
| Total Stockholder Equity Past Year | 22,149,000 |
| Total Stockholder Equity Prior Year | 51,099,000 |
| Total Stockholder Equity Most Recent Quarter | 61,619,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -109,127,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.25 |
| Free Cash Flow Past Year | -131,227,000 |
| Free Cash Flow Prior Year | -96,572,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.42 |
| RSI | 0.00 |
| 50-Day SMA | 21.56 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 25.85 |
System |
|
| Modified | 1/31/2026 10:59:46 AM EST |